A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-05221304 ADMINISTERED DAILY FOR 16-WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-05221304 ADMINISTERED DAILY FOR 16-WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92037, United States
Chapel Hill, North Carolina 27514, United States
Chapel Hill, North Carolina 27599, United States
Chapel Hill, North Carolina 27599, United States
Adelaide, South Australia 5000, Australia
Adelaide, South Australia 5042, Australia
Toronto, Ontario M5G 2C4, Canada
Montreal, Quebec H4A 3J1, Canada
Québec, Quebec G1V 4G2, Canada
Québec, Quebec G1V 4G5, Canada
Sherbrooke, Quebec J1G 2E8, Canada